U.S., May 30 -- ClinicalTrials.gov registry received information related to the study (NCT07615166) titled 'Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical Practice' on May 22.
Brief Summary: The objective of this study is to evaluate LDL-C reduction over time among individuals initiating alirocumab 150 mg compared with inclisiran in routine clinical practice. The study will leverage observational data reflective of routine care and apply contemporary methods in target trial emulation and causal inference to estimate comparative treatment effects.
Study Start Date: May 22, 2025
Study Type: OBSERVATIONAL
Condition:
Atherosclerotic Cardiovascular...